LABT
Lakewood-Amedex Biotherapeutics Inc.Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.24x | — |
Current ratio Current assets over current liabilities. | 0.13x | 4.17x | 414 / 419 |
Quick ratio Current assets excluding inventory, over current liabilities. | 0.13x | 3.84x | 411 / 419 |
Interest coverage Operating income divided by interest expense. | Not reported | -15.21x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.56x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Annual financials
| Fiscal year | 2026 |
|---|---|
| Total assets | $481.6K |
| Shareholder equity | -$1.96M |
| Cash | $236.4K |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from Lakewood-Amedex Biotherapeutics Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-Q filed May 22, 2026. View filings on EDGAR.